DK0971709T3 - Hidtil ukendte forbindelser nyttige som neurobeskyttende midler - Google Patents

Hidtil ukendte forbindelser nyttige som neurobeskyttende midler

Info

Publication number
DK0971709T3
DK0971709T3 DK97909975T DK97909975T DK0971709T3 DK 0971709 T3 DK0971709 T3 DK 0971709T3 DK 97909975 T DK97909975 T DK 97909975T DK 97909975 T DK97909975 T DK 97909975T DK 0971709 T3 DK0971709 T3 DK 0971709T3
Authority
DK
Denmark
Prior art keywords
compounds useful
new compounds
neuroprotective agents
agents
neuroprotective
Prior art date
Application number
DK97909975T
Other languages
Danish (da)
English (en)
Inventor
J Heinz Lawrence
A Panetta Jill
L Phillips Michael
K Shadle John
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0971709T3 publication Critical patent/DK0971709T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Liquid Crystal Substances (AREA)
DK97909975T 1996-10-07 1997-10-06 Hidtil ukendte forbindelser nyttige som neurobeskyttende midler DK0971709T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2756096P 1996-10-07 1996-10-07
PCT/US1997/017963 WO1998015274A1 (en) 1996-10-07 1997-10-06 Novel compounds useful as neuro-protective agents

Publications (1)

Publication Number Publication Date
DK0971709T3 true DK0971709T3 (da) 2003-09-22

Family

ID=21838447

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97909975T DK0971709T3 (da) 1996-10-07 1997-10-06 Hidtil ukendte forbindelser nyttige som neurobeskyttende midler

Country Status (19)

Country Link
US (4) US6156748A (cs)
EP (1) EP0971709B1 (cs)
CN (1) CN1239889A (cs)
AT (1) ATE240728T1 (cs)
AU (1) AU721355B2 (cs)
CA (1) CA2270661A1 (cs)
CZ (1) CZ166399A3 (cs)
DE (1) DE69722258T2 (cs)
DK (1) DK0971709T3 (cs)
EA (1) EA001713B1 (cs)
ES (1) ES2199353T3 (cs)
HU (1) HUP9904682A3 (cs)
ID (1) ID21472A (cs)
IL (1) IL129748A (cs)
NO (1) NO313193B1 (cs)
NZ (1) NZ335610A (cs)
PT (1) PT971709E (cs)
TR (1) TR199901559T2 (cs)
WO (1) WO1998015274A1 (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942530A (en) * 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
CA2302294A1 (en) * 1997-08-28 1999-03-04 Harlan Edgar Shannon Method for treating pain
US5952360A (en) * 1997-08-28 1999-09-14 Eli Lilly And Company Method for treating neuropathic pain
CA2305538A1 (en) 1997-10-06 1999-04-15 David Lee Varie Novel compounds useful as neuro-protective agents
DE19816880A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
EP1218336A2 (en) 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
RU2380362C2 (ru) * 1999-10-11 2010-01-27 Сосьете Де Консей Де Решерш З Производные пятичленных гетероциклов, способ их получения и их применение в качестве лекарственных средств
FR2812546B1 (fr) * 2000-08-01 2008-11-21 Sod Conseils Rech Applic Derives d'heterocycles a 5 chainons, leur preparation et leur application a titre de medicaments
EP1285651B1 (en) 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonists
JP2004531479A (ja) * 2001-02-08 2004-10-14 カロ バイオ アクチェブラーグ 甲状腺受容体リガンドとしてのフェノキシ置換されたベンゾ縮合ヘテロアリール誘導体
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
WO2004005267A2 (en) 2002-07-03 2004-01-15 Janssen Pharmaceutica, N.V. Heteroaryl compounds useful in treating inflammatory disorders
EP1599216B9 (en) * 2003-02-04 2015-02-11 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
TW200505913A (en) 2003-03-28 2005-02-16 Hoffmann La Roche Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
US7353897B2 (en) * 2003-07-23 2008-04-08 Fernandez Dennis S Telematic method and apparatus with integrated power source
CA3024434A1 (en) 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
PL1954684T3 (pl) 2005-11-15 2014-10-31 Otsuka Pharma Co Ltd Związek oksazolowy i kompozycja farmaceutyczna
EP2614549B1 (de) 2010-09-06 2016-04-27 Aigys AG Betankbarer akku
US10881162B2 (en) 2015-05-07 2021-01-05 Exero Labs LLC Device for minimizing impact of collisions for a helmet
CN112826794B (zh) 2019-11-06 2022-02-11 上海交通大学医学院 一种靶向修复神经血管病变的纳米复合物及其制备与应用
WO2024040267A2 (en) * 2022-08-19 2024-02-22 Mitokinin, Inc. Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636516A (en) * 1981-02-19 1987-01-13 Yamanouchi Pharmaceutical Co., Ltd. 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compounds
DE3425118A1 (de) * 1984-07-07 1986-01-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue redox-indikatoren
GB8531608D0 (en) * 1985-12-23 1986-02-05 Beecham Group Plc Treatment
DE3621775A1 (de) * 1986-03-13 1988-01-07 Thomae Gmbh Dr K Neue substituierte thiazole und oxazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3903993A1 (de) * 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
CA2009470A1 (en) * 1989-02-08 1990-08-08 Yu Momose Oxazole compounds and their use
ES2092580T3 (es) * 1990-11-30 1996-12-01 Teijin Ltd Derivado de 2-ariltiazol y composicion farmaceutica que contiene el mismo.
US5633271A (en) * 1992-05-26 1997-05-27 E. I. Du Pont De Nemours And Company Arthropodicidal oxazolines and thiazolines
DE4304197A1 (de) * 1993-02-12 1994-08-18 Bayer Ag Substituierte Oxazole
US5428048A (en) * 1993-11-08 1995-06-27 American Home Products Corporation Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5942530A (en) * 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
CA2302294A1 (en) * 1997-08-28 1999-03-04 Harlan Edgar Shannon Method for treating pain
US5952360A (en) * 1997-08-28 1999-09-14 Eli Lilly And Company Method for treating neuropathic pain
CA2305538A1 (en) * 1997-10-06 1999-04-15 David Lee Varie Novel compounds useful as neuro-protective agents

Also Published As

Publication number Publication date
US20020065274A1 (en) 2002-05-30
NO992226D0 (no) 1999-05-07
US6423709B1 (en) 2002-07-23
HUP9904682A2 (hu) 2000-05-28
CZ166399A3 (cs) 1999-11-17
NO992226L (no) 1999-05-27
DE69722258D1 (de) 2003-06-26
HUP9904682A3 (en) 2001-09-28
ES2199353T3 (es) 2004-02-16
AU4745997A (en) 1998-05-05
US6156748A (en) 2000-12-05
ATE240728T1 (de) 2003-06-15
EP0971709B1 (en) 2003-05-21
PT971709E (pt) 2003-09-30
NZ335610A (en) 2000-10-27
AU721355B2 (en) 2000-06-29
TR199901559T2 (xx) 1999-09-21
ID21472A (id) 1999-06-17
IL129748A0 (en) 2000-02-29
US6166216A (en) 2000-12-26
EP0971709A4 (en) 2001-04-11
IL129748A (en) 2003-11-23
EA199900362A1 (ru) 2000-02-28
CA2270661A1 (en) 1998-04-16
EA001713B1 (ru) 2001-08-27
EP0971709A1 (en) 2000-01-19
DE69722258T2 (de) 2004-03-18
NO313193B1 (no) 2002-08-26
WO1998015274A1 (en) 1998-04-16
CN1239889A (zh) 1999-12-29
US6380213B1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
DK0971709T3 (da) Hidtil ukendte forbindelser nyttige som neurobeskyttende midler
TR199800679T2 (xx) Kiral metil fenil oksazolidinon.
TR200103612T2 (tr) Tiazol ve oksazol türevleri ve farmasötik kullanımları
UY34152A (es) ?oxazolidinonas substituidas y su uso?.
DK1349843T3 (da) Thiazol- og oxazolderivater som aktivatorer af human peroxisom profilerator-aktiverede receptorer
ATE264313T1 (de) Substituierte oxazole und thiazole derivate als hppar-gamma und hppar-alpha aktivatore
DK1244642T3 (da) Substituerede oxazol- og thiazolderivater som HPPAR-alfa-aktivatorer
DE59913784D1 (de) Verwendung von Thiazolidinderivaten als antihyperglykämische Mittel
NO995846D0 (no) Oksazolidinon-antibakterielle midler med en tiokarbonylfunksjonalitet
DK0699192T3 (da) Substituerede oxazolylforbindelser til behandling af inflammation
DE60024414D1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
NO20062629L (no) Oksazolderivater av tetrackliner
EP0908454A3 (en) Oxazoles, thiazoles, oxazolines, oxadiazoles and benzoxazoles useful as neuro-protective agents
BG105539A (bg) Елетриптан хидробромид монохидрат
ATE320422T1 (de) Metalloproteinase inhibitoren
DE60223805D1 (de) Oxazol/thiazol-derivate als aktivatoren des hppar-alpha-rezeptors
ATE412413T1 (de) Oxazolidin tablettenformulierung
DK0703915T3 (da) Hetrocyklisk kemi
EP0270482A3 (en) Use of 5-(substituted phenyl-)oxazolidinones in the treatment of depressions
NO20032582L (no) 1,2,4-oksadiazolderivater som HPPAR alfa agonister
ATE323493T1 (de) Gesteuerte freisetzung von antidepressiva
TR200103240T2 (tr) Endoparazit öldürücü bileşimler.
ATE224928T1 (de) Polyketonpolymer-zusammensetzung
ATE202101T1 (de) Sulfonylbenzazolone
NO982879L (no) Vannlöselige antibiotika